Alnylam Pharmaceuticals, Inc.

ALNYintermediary

Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference (RNAi) therapeutics, a revolutionary approach to treating disease by silencing the genes that cause it. Its ATTR franchise has established RNAi as a validated drug modality, and its deep pipeline across cardiometabolic, CNS, and infectious diseases promises to expand the platform's reach.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($2.4B)

Data statis (memuat keuangan langsung…)

ATTR Franchise (Amvuttra/Onpattro) (65%)

Royalties & Collaboration (Leqvio) (25%)

Other Pipeline Revenue (10%)

Komposisi segmen dan pelanggan utama

Detail produk

Onpattro (Patisiran)30%

First FDA-approved RNAi therapeutic for hereditary ATTR amyloidosis

Amvuttra (Vutrisiran)40%

Subcutaneous RNAi treatment for ATTR polyneuropathy (quarterly dosing)

Leqvio (Inclisiran)30%

RNAi cholesterol-lowering drug partnered with Novartis

Hubungan Rantai Pasok

Mitra

Regeneron Pharmaceuticals

RNAi research collaboration

Dampak: Strategic R&D alliance

Eli Lilly and Company

Potential licensing discussions

Dampak: Pharma partnership potential

Pesaing

Moderna, Inc.

RNA-based therapeutic modalities

Dampak: Competing RNA platforms

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Alnylam Pharmaceuticals, Inc..

Info Perusahaan

Kantor Pusat

Cambridge, Massachusetts, USA

Didirikan

2002

Karyawan

2,800+

Situs Web

alnylam.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor